| Year | Citation | Score | |||
|---|---|---|---|---|---|
| 2019 | Prutsch N, Jing C, Etchin J, Berezovskaya A, Tiv H, Poitras MJ, Gokhale P, Landesman Y, Look AT. Abstract 2953: Selective activity of XPO1 inhibitors in TET2-mutant myeloid malignancies Cancer Research. 79: 2953-2953. DOI: 10.1158/1538-7445.Am2019-2953 | 0.403 | |||
| 2017 | Akahane K, Li Z, Etchin J, Berezovskaya A, Gjini E, Masse CE, Miao W, Rocnik J, Kapeller R, Greenwood JR, Tiv H, Sanda T, Weinstock DM, Look AT. Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia. British Journal of Haematology. PMID 28295194 DOI: 10.1182/Blood.V128.22.1596.1596 | 0.423 | |||
| 2017 | Abraham BJ, Hnisz D, Weintraub AS, Kwiatkowski N, Li CH, Li Z, Weichert-Leahey N, Rahman S, Liu Y, Etchin J, Li B, Shen S, Lee TI, Zhang J, Look AT, et al. Small genomic insertions form enhancers that misregulate oncogenes. Nature Communications. 8: 14385. PMID 28181482 DOI: 10.1038/Ncomms14385 | 0.336 | |||
| 2017 | Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. Abstract 39: XPO1 inhibitor, KPT-8602, is well tolerated and highly active against AML blasts and LICs Clinical Cancer Research. 23: 39-39. DOI: 10.1158/1557-3265.Hemmal17-39 | 0.472 | |||
| 2016 | Etchin J, Berezovskaya A, Conway AS, Galinsky IA, Stone RM, Baloglu E, Senapedis W, Landesman Y, Kauffman M, Shacham S, Wang JC, Look AT. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. PMID 27211268 DOI: 10.1038/Leu.2016.145 | 0.477 | |||
| 2016 | Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, ... ... Etchin J, et al. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 29: 574-86. PMID 27070704 DOI: 10.1016/J.Ccell.2016.03.008 | 0.385 | |||
| 2015 | Etchin J, Montero J, Berezovskaya A, Le BT, Kentsis A, Christie AL, Conway AS, Chen WC, Reed C, Mansour MR, Ng CE, Adamia S, Rodig SJ, Galinsky IA, Stone RM, et al. Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-Initiating cells engrafted into immunosuppressed NSG mice. Leukemia. PMID 26202935 DOI: 10.1038/Leu.2015.194 | 0.465 | |||
| 2015 | Etchin J, Berezovskaya A, Saur Conway A, Chen WC, Baloglu E, Landesman Y, Senapedis W, Ellis J, McCauley D, Stone RM, Galinsky I, DeAngelo DJ, Kauffman M, Shacham S, Wang JC, et al. Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML Blood. 126: 326-326. DOI: 10.1182/Blood.V126.23.326.326 | 0.477 | |||
| 2015 | Murakami MA, Christodoulou AN, Christie AL, DeSouza T, Louissaint A, Vojinovic U, Koch R, Li LS, Kallgren SP, Rao P, Köster J, Vadhi R, Duberow E, Morgan EA, Wang H, ... ... Etchin J, et al. Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma Blood. 126: 3252-3252. DOI: 10.1182/Blood.V126.23.3252.3252 | 0.413 | |||
| 2015 | Etchin J, Le BT, Berezovskaya A, Conway AS, Chen WC, Kentsis A, Mansour MR, Stone RM, Galinsky IA, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JC, Kung AL, et al. Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells Cancer Research. 75: 4445-4445. DOI: 10.1158/1538-7445.Am2015-4445 | 0.516 | |||
| 2014 | Mansour MR, Abraham BJ, Anders L, Berezovskaya A, Gutierrez A, Durbin AD, Etchin J, Lawton L, Sallan SE, Silverman LB, Loh ML, Hunger SP, Sanda T, Young RA, Look AT. Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science (New York, N.Y.). 346: 1373-7. PMID 25394790 DOI: 10.1126/Science.1259037 | 0.385 | |||
| 2014 | Barceló C, Etchin J, Mansour MR, Sanda T, Ginesta MM, Sanchez-Arévalo Lobo VJ, Real FX, Capellà G, Estanyol JM, Jaumot M, Look AT, Agell N. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology. 147: 882-892.e8. PMID 24998203 DOI: 10.1053/J.Gastro.2014.06.041 | 0.331 | |||
| 2014 | Etchin J, Le BT, Kentsis A, Mansour MR, Berezovskaya A, Stone RM, Galinsky I, DeAngelo DJ, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells Blood. 124: 995-995. DOI: 10.1182/Blood.V124.21.995.995 | 0.45 | |||
| 2013 | Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, Christie AL, McCauley D, Rodig SJ, Kauffman M, Shacham S, Stone R, Letai A, Kung AL, Thomas Look A. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. British Journal of Haematology. 161: 117-27. PMID 23373539 DOI: 10.1111/Bjh.12231 | 0.479 | |||
| 2013 | Etchin J, Sun Q, Kentsis A, Farmer A, Zhang ZC, Sanda T, Mansour MR, Barcelo C, McCauley D, Kauffman M, Shacham S, Christie AL, Kung AL, Rodig SJ, Chook YM, et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia. 27: 66-74. PMID 22847027 DOI: 10.1038/Leu.2012.219 | 0.445 | |||
| 2013 | Etchin J, Le BT, Kentsis A, Stone RM, McCauley D, Kauffman M, Shacham S, Wang JCY, Kung AL, Look AT. Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML “primagrafts,” Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells Blood. 122: 3932-3932. DOI: 10.1182/Blood.V122.21.3932.3932 | 0.502 | |||
| 2013 | Akahane K, Sanda T, Mansour MR, Etchin J, Cherry N, Weinstock DM, Letai A, DeAngelo DJ, Look AT. HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase Blood. 122: 2528-2528. DOI: 10.1182/Blood.V122.21.2528.2528 | 0.434 | |||
| 2012 | Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look AT. Evaluation of KPT-SINE (Selective Inhibitors of CRM1-Mediated Nuclear Export) in AML and T-ALL. Journal of Clinical Oncology. 30: e13586-e13586. DOI: 10.1200/Jco.2012.30.15_Suppl.E13586 | 0.485 | |||
| 2011 | Etchin J, Kanki JP, Look AT. Zebrafish as a model for the study of human cancer. Methods in Cell Biology. 105: 309-37. PMID 21951536 DOI: 10.1016/B978-0-12-381320-6.00013-8 | 0.313 | |||
| 2011 | Etchin J, Kentsis A, Sanda T, Kung AL, Stone RM, McCauley D, Kauffman M, Shacham S, Look T. KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML Blood. 118: 2622-2622. DOI: 10.1182/Blood.V118.21.2622.2622 | 0.482 | |||
| 2010 | Dray E, Etchin J, Wiese C, Saro D, Williams GJ, Hammel M, Yu X, Galkin VE, Liu D, Tsai MS, Sy SM, Schild D, Egelman E, Chen J, Sung P. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nature Structural & Molecular Biology. 17: 1255-9. PMID 20871616 DOI: 10.1038/Nsmb.1916 | 0.472 | |||
| 2010 | Gutierrez A, Kentsis A, Sanda T, Etchin J, Protopopov A, Zhang J, Chin L, Silverman LB, Winter S, Hunger S, Sallan SE, Zha S, Alt F, Look AT. The BCL11B Tumor Suppressor Is Mutated In Human T-Cell Acute Lymphoblastic Leukemia Blood. 116: 4177-4177. DOI: 10.1182/Blood.V116.21.4177.4177 | 0.414 | |||
| 2006 | San Filippo J, Chi P, Sehorn MG, Etchin J, Krejci L, Sung P. Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide. The Journal of Biological Chemistry. 281: 11649-57. PMID 16513631 DOI: 10.1074/Jbc.M601249200 | 0.455 | |||
| Show low-probability matches. | |||||